Use of effective contraceptive methods among women taking teratogenic medications for systemic lupus erythematosus

      Women with systemic lupus erythematosus (SLE) are advised to plan their pregnancies for periods of disease quiescence and minimized teratogen exposure. Most are candidates for extremely effective contraceptive methods (EECM) (typical use failure rate ���3%) including depomedroxyprogesterone acetate, implants, intrauterine contraceptive devices or permanent sterilization. However, these methods are often underutilized. This study aims to assess whether women with SLE who are at risk for pregnancy and using specific teratogenic medications (methotrexate, mycophenolate mofetil, cyclophosphamide, alendronate sodium or leflunomide) are also using EECM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect